List of Figures
Figure 1: Breast Cancer Therapeutics, APAC, Age-Standardized Incidence (per 100,000 population), 2012 16
Figure 2: Breast Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2012, 2013 and 2014 17
Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I–III 26
Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV 27
Figure 5: Breast Cancer Therapeutics Market, Global, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of HER2-Positive Breast Cancer Patients, 2018 54
Figure 6: Breast Cancer Therapeutics Market, Global, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of HER2-Negative Breast Cancer Patients, 2018 56
Figure 7: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products, 2018 63
Figure 8: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline 65
Figure 9: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline 66
Figure 10: Breast Cancer Therapeutics Market, APAC, Neratinib, Market Forecast ($m), 2020–2024 69
Figure 11: Breast Cancer Therapeutics Market, APAC, Abemaciclib, Market Forecast ($m), 2018–2024 71
Figure 12: Breast Cancer Therapeutics Market, APAC, Olaparib, Market Forecast ($m), 2018–2024 73
Figure 13: Breast Cancer Therapeutics Market, APAC, Talazoparib, Market Forecast ($m), 2020–2024 75
Figure 14: Breast Cancer Therapeutics Market, APAC, Pembrolizumab, Market Forecast ($m), 2020–2024 77
Figure 15: Breast Cancer Therapeutics Market, APAC, Atezolizumab Forecast ($m), 2021–2024 79
Figure 16: Breast Cancer Therapeutics Market, APAC, Taselisib, Market Forecast ($m), 2020–2024 81
Figure 17: Breast Cancer Therapeutics Market, APAC, Alpelisib, Market Forecast ($m), 2021–2024 83
Figure 18: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for HER2-Positive Breast Cancer, 2018 89
Figure 19: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for HER2-Negative Breast Cancer, 2018 90
Figure 20: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for TNBC, 2018 91
Figure 21: Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Positive Breast Cancer Marketed and Pipeline Products, 2018 92
Figure 22: Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Negative Breast Cancer Marketed and Pipeline Products, 2018 93
Figure 23: Breast Cancer Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2007–2017 95
Figure 24: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007–2017 96
Figure 25: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007–2017 97
Figure 26: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2007–2017 98
Figure 27: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2007–2017 99
Figure 28: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007–2017 100
Figure 29: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2007–2017 101
Figure 30: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2007–2017 102
Figure 31: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2007–2017 103
Figure 32: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 104
Figure 33: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 105
Figure 34: Breast Cancer Therapeutics Market, APAC, Treatment Patterns (‘000), 2017–2024 108
Figure 35: Breast Cancer Therapeutics Market, APAC, Market Size ($bn), 2017–2024 110
Figure 36: Breast Cancer Therapeutics Market, India, Treatment Patterns (‘000), 2017–2024 111
Figure 37: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2017–2024 112
Figure 38: Breast Cancer Therapeutics Market, India, Market Size ($m), 2017–2024 113
Figure 39: Breast Cancer Therapeutics Market, China, Treatment Patterns (‘000), 2017–2024 115
Figure 40: Breast Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2017–2024 116
Figure 41: Breast Cancer Therapeutics Market, China, Market Size ($m), 2017–2024 118
Figure 42: Breast Cancer Therapeutics Market, Australia, Treatment Patterns (‘000), 2017–2024 119
Figure 43: Breast Cancer Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017–2024 120
Figure 44: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2017–2024 121
Figure 45: Breast Cancer Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017–2024 122
Figure 46: Breast Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017–2024 123
Figure 47: Breast Cancer Therapeutics Market, South Korea, Market Size ($m), 2017–2024 125
Figure 48: Breast Cancer Therapeutics Market, Japan, Treatment Patterns (‘000), 2017–2024 126
Figure 49: Breast Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017–2024 127
Figure 50: Breast Cancer Therapeutics Market, Japan, Market Size ($bn), 2017–2024 129
Figure 51: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2007–2017 135
Figure 52: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2017 136
Figure 53: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007–2017 137
Figure 54: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007–2017 138
Figure 55: Breast Cancer Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007–2017 139
Figure 56: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2007–2017 142
Figure 57: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2017 143
Figure 58: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2007–2017 144
Figure 59: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2007–2017 145
Figure 60: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007–2017 146